Hot Topics in Drug Development [April 2016]
8
Click * at the end of each summary to
access the full news item online.
PATIENTS WILLING TO SHARE
RESEARCH DATA
As debate swirls about a recent
Institute of Medicine report suggesting
that electronic health records collect
more non-clinical patient data for
population health research, a new poll
suggest patients are mostly willing to
offer access to anonymized health
information – to an extent.
*
Read more here:
http://www.healthcareitnews.com/new
s/patients-willing-share-research-data
MICROSOFT CO-FOUNDER
COMMITS $100M TO EARLY-STAGE
RESEARCH AT INTERSECTION OF IT
AND BIOLOGY
Paul Allen, the co-founder of
Microsoft has committed $100 million
to create The Paul G. Allen Frontiers
Group, an early-stage bioscience fund.
And, in keeping with Allen's
background and other forays into
bioscience, the fund's initial
investments in macrophage modeling
and other fields have a computational
slant.
*
Read more here:
http://www.fiercebiotechit.com/story/
microsoft-co-founder-commits-100m-
early-stage-research-intersection-it-
and/2016-03-28?utm_content=
bufferd9ca2&utm;_medium=social&ut;
m_source=linkedin.com&utm;_campai
gn=buffer
CALIFF SEEKS CLINICAL TRIALS
THAT INFORM PRODUCT LABELS
Newly confirmed FDA
Commissioner Robert Califf has long
advocated for a "learning healthcare
system" that supports clinical research
by tapping electronic health records to
facilitate clinical trial enrollment and
provide ongoing information on the
effects and side-effects of therapies in
real-world use. Now at the helm of
FDA, Califf has a ready platform to
discuss such strategies for improving
clinical trial methodology, execution
and evaluation as part of the larger
goal of developing more innovative
treatments for patients.
*
Read more here:
http://www.pharmexec.com/califf-
seeks-clinical-trials-inform-product-
labels-
0?utm_content=buffer748bb&utm;_me
dium=social&utm;_source=linkedin.co
m&utm;_campaign=buffer
EUROPE LAUNCHES PROGRAM FOR
FASTER DRUG APPROVALS
The European Medicines Agency
(EMA) launched a new initiative
recently called PRIME, which is
designed to help expedite the
regulatory process for drug makers
working on promising medications for
rare diseases.
*
Read more here:
http://www.dddmag.com/news/2016/03/
europe-launches-program-faster-drug-
approvals?utm_content=
buffera7bc9&utm;_medium=social&ut;
m_source=linkedin.com&utm;_campaig
n=buffer
SURVEY: NEED FOR INCREASED
CONSUMER CLINICAL TRIALS
EDUCATION
SubjectWell, provider of a risk-free
patient recruitment marketplace for
clinical trials, has released its report on
consumer perceptions of clinical trials.
The SubjectWell Survey of Clinical
Trial Awareness and Attitudes reveals
significant education is still needed
around the existence of clinical trials.
Half of those surveyed (50%) had
never heard of clinical trials, and only
31% felt confident or very confident
that they would know how to get
information about clinical trials.
*
Read more here:
http://www.centerwatch.com/news-
online/2016/03/02/25719/?utm_content
=bufferc91ea&utm;_medium=social&ut;
m_source=linkedin.com&utm;_campaig
n=buffer
RESEARCHERS OF ALZHEIMER'S,
OTHER NEUROLOGICAL DISEASES
SAY 'MINI-BRAINS' MAY BE
EFFECTIVE IN TESTING NEW
DRUGS
Researchers at the Johns Hopkins
Bloomberg School of Public Health
have developed "mini-brains" that may
present a more accurate and effective
way of testing new drugs for many
neurological disorders, such as
Alzheimer's disease. These human cell-
derived structures, which represent an
In the News
Exploring Drug Development
in the Media